Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Clinical trial NCT06846320 · RECRUITING

Trial details

NCT number: NCT06846320
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Generalized Anxiety Disorder (GAD)

Start date: 2025-04-29
Primary completion: 2026-11-01
Enrollment: 315

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.